Category: Pharma- biotech- Patent Commercialisation

The Nagoya Protocol – Convention on Biological Diversity

21st July, 2014 - 9:10 am Categories: News & Updates Patent Commercialisation Patents Pharma- biotech- Patent Commercialisation

A new international treaty named the “Nagoya Protocol” will be giving some relief to India and other developing countries. The Nagoya Protocol on Access to Genetic Resources with an objective of ensuring access of genetic resources to the signatory countries and ensuring fair and equitable sharing of benefit to the local community and signatory country that … Continue reading The Nagoya Protocol – Convention on Biological Diversity

Read more »

Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

13th December, 2013 - 7:42 am Categories: Educational Conferences/ Seminar News & Updates Pharma- biotech- Patent Commercialisation

We are happy to inform you all that IIPRD and Khurana & Khurana, in association with Cantor Colburn (US) and Fukami Patent Office (Japan) are holding an International Patent Symposium covering all major and relevant Pharmaceutical/Biotechnology Related Patent issues in the month of February, 2014 in India. The Two-Days International Symposium would be covering Strategies for Managing … Continue reading Two-Days International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios

Read more »

NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

14th September, 2011 - 4:38 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Natco Pharma has filed India’s first Compulsory Licensing (CL) Application (in accordance with Section 84(1) of the Indian Patents Act) against one of the Bayer’s patented drug Sorafenib, marketed by Bayer as Nexavar for treating Kidney and Liver Cancer. Patent on Sorafenib is granted in India on 03.03.2008 having number IN 215758. This will be … Continue reading NATCO FILES INDIA’S FIRST COMPULSORY LICENSING APPLICATION

Read more »

Inventors, All Technologies Aren’t Worth Billions

31st July, 2011 - 6:23 pm Categories: Hi Tech Patent Commercialisation Patent Commercialisation Pharma- biotech- Patent Commercialisation

Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite of lot about Inventors mindset, specifically about their perspective of their own inventions. This article relates to our … Continue reading Inventors, All Technologies Aren’t Worth Billions

Read more »

Anti Cancer drug: Making it Patient-driven, not Disease-driven

11th April, 2011 - 10:16 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Introduction: French compatriots Ipsen and bioMérieux, have been few most potential companies, since 2007 in the development of companion assay to assess patient benefit from a compound useful for treating several severe forms of cancers.Partnership between two companies has focused on the two main broad areas of pharma research: Personalized medicine and Theronostics. Personalized medicine … Continue reading Anti Cancer drug: Making it Patient-driven, not Disease-driven

Read more »

Food Market making Profit from Climatic Changes

14th March, 2011 - 7:15 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Climatic changes being a source of making profit for food crop manufacturers. Adverse changes in climate has triggered the ecosystems affecting crops, livestock, fisheries and forests and the billions of people whose livelihoods depend on them. Extreme climate events (especially hotter, drier conditions in semi-arid regions) are likely to slash yields for maize, wheat, rice … Continue reading Food Market making Profit from Climatic Changes

Read more »

Indian Pharmaceutical Industry Licensing Deals: Case Studies

14th June, 2010 - 10:36 am Categories: Patent Commercialisation Pharma- biotech- Patent Commercialisation

Glenmark Pharmaceuticals Glenmark, research-driven, global, integrated pharmaceutical company with Research Focus on Inflammatory Diseases, Metabolic Disorders and Pain has a presence in over 80 countries around the world. The Company has a proven track record of entering into Licensing deals with Big Pharma and entered into Outlicensing deals in 2004 with Forest laboratories for Oglemilast, … Continue reading Indian Pharmaceutical Industry Licensing Deals: Case Studies

Read more »

Categories

Archives